Creative Bioarray has launched a comprehensive hERG safety assay service aimed at enhancing drug development processes by identifying potential cardiotoxic risks earlier in research. The service addresses a critical safety concern in pharmaceutical development, where blockage of hERG potassium channels can lead to life-threatening cardiac side effects, making early detection essential for both patient safety and development efficiency.
The company's new service optimizes traditional screening methods by integrating modern technologies to deliver high-throughput, reliable results. According to Hannah Cole, a spokesperson for Creative Bioarray, the service provides a vital tool for pharmaceutical companies and researchers looking to streamline their drug development process. "Our advanced testing methods provide the critical information needed to make informed decisions and ensure the safety of new therapies," Cole stated.
Creative Bioarray's approach includes detailed data interpretations to help scientists optimize lead compounds while reducing the risk of late-stage drug development failure due to cardiotoxicity. The service is designed to benefit a wide range of stakeholders in the pharmaceutical industry, including biotechnology companies, contract research organizations (CROs), and academic institutions. By integrating this safety assay into early development stages, companies can improve project efficiency and potentially bring safe drugs to market faster.
The company has cultivated a team of experienced experts with extensive expertise in pharmacology, electrophysiology, and drug safety assessment. This expertise provides clients with not only highly accurate assays but also comprehensive analysis and guidance throughout the research process. In addition to hERG safety testing, Creative Bioarray offers a range of other bioassays, customized services, and products to meet the specific needs of modern research environments.
The importance of this development lies in its potential to address one of the most significant challenges in drug development: late-stage failures due to safety concerns. According to industry data available at https://www.fda.gov/drugs, cardiotoxicity remains a leading cause of drug development setbacks and withdrawals. By providing more reliable early screening, Creative Bioarray's service could help reduce development costs and timelines while improving patient safety outcomes.
For researchers seeking additional information about cardiac safety testing protocols, resources are available through organizations like the https://www.ich.org, which establishes international guidelines for pharmaceutical development. The launch of this service represents a significant advancement in safety screening technology that could have broad implications for how pharmaceutical companies approach early-stage development and risk assessment.
